title: Nilotinib rapidly reverses breakpoint cluster region-Abelson oncogene fusion gene and M244V mutations in a patient with chronic myelogenous leukemia: A case report.
abstract: Chronic myelogenous leukemia (CML) is a condition characterized by a balanced genetic translocation, t (9;22) (q34;q11.2), which leads to a fusion of the Abelson oncogene (ABL) from chromosome 9q34 with the breakpoint cluster region (BCR) gene on chromosome 22q11.2. This rearrangement is referred to as the Philadelphia chromosome. At a molecular level, this translocation results in the formation of theBCR-ABLfusion oncogene, which translates into a BCR-ABL oncoprotein. Imatinib, nilotinib and dasatinib are three tyrosine kinase inhibitors that have been approved by the US Food and Drug Administration for the treatment of patients diagnosed with CML in the chronic phase (CML-CP). The present study describes the case of a patient with imatinib-resistant CML who, following two months of treatment with nilotinib, no longer exhibited detectableBCR-ABLfusion genes or M244V mutations. This suggests that nilotinib may be effective for treating CML cases in which the BCR-ABL fusion protein has an M244V mutation.
authors.affiliation: Department of Hematology, Heping Hospital of Changzhi Medical College, Changzhi, Shanxi 046000, P.R. China.
authors.forename: Xuliang
authors.initials: X
authors.lastname: Shen
authors.affiliation: Department of Hematology, Beijing Rehabilitation Hospital of Capital Medical University, Beijing 100144, P.R. China.
authors.forename: Meixiang
authors.initials: M
authors.lastname: Zhang
authors.affiliation: Department of Hematology, Heji Hospital of Changzhi Medical College, Changzhi, Shanxi 046000, P.R. China.
authors.forename: Yifan
authors.initials: Y
authors.lastname: Shen
authors.affiliation: Department of Hematology, Heping Hospital of Changzhi Medical College, Changzhi, Shanxi 046000, P.R. China.
authors.forename: Wenzhi
authors.initials: W
authors.lastname: Shi
authors.affiliation: Department of Hematology, Heping Hospital of Changzhi Medical College, Changzhi, Shanxi 046000, P.R. China.
authors.forename: Wei
authors.initials: W
authors.lastname: Liu
authors.affiliation: Department of Hematology, Heping Hospital of Changzhi Medical College, Changzhi, Shanxi 046000, P.R. China.
authors.forename: W U
authors.initials: WU
authors.lastname: Wei
keywords: M244V mutation; breakpoint cluster region-Abelson oncogene; chronic myeloid leukemia; nilotinib; tyrosine kinase inhibitors